Ganovo® is the commercial brand name of Danoprevir Sodium Tablets, an orally active HCV NS3/4A protease inhibitor developed by Ascletis Pharma. It blocks hepatitis C virus protease to hinder viral protein cleavage and suppress HCV replication. Main IndicationsUsed in combination…
Vemlidy® is the commercial brand name of Tenofovir Alafenamide Fumarate Tablets, an orally active nucleotide reverse transcriptase inhibitor developed by Gilead Sciences. It inhibits hepatitis B virus replication by blocking viral reverse transcriptase to suppress HBV DNA synthesis. Main IndicationsTreatment…
Deltyba® is the commercial brand name of Delamanid Tablets, an orally active nitroimidazole anti-tuberculosis drug developed by Otsuka Pharmaceutical. It interferes with mycobacterial cell wall synthesis to exert bactericidal activity against drug-resistant Mycobacterium tuberculosis. Main IndicationsCombined treatment for adult patients…
Sirturo® is the commercial brand name of Bedaquiline Fumarate Tablets, an orally active diarylquinoline anti-tuberculosis agent developed by Janssen. It inhibits mycobacterial ATP synthase to block bacterial energy synthesis and exert bactericidal activity against multidrug-resistant Mycobacterium tuberculosis. Main IndicationsCombination therapy…
Noxafil® is the commercial brand name of Posaconazole Enteric-coated Tablets, an orally active triazole antifungal developed by MSD. It inhibits fungal lanosterol synthesis by blocking cytochrome P450-dependent 14α-demethylase, resulting in fungal cell membrane damage and bacteriostatic/fungicidal effects. Main IndicationsProphylaxis of…
Florinef® is the commercial brand name of Fludrocortisone Acetate Tablets, an orally active synthetic mineralocorticoid developed by Aspen Pharma. It enhances renal sodium reabsorption and potassium excretion to expand blood volume and regulate electrolyte balance in the body. Main IndicationsReplacement…
Kerendia® is the commercial brand name of Finerenone Tablets, an orally active nonsteroidal mineralocorticoid receptor antagonist developed by Bayer. It selectively blocks mineralocorticoid receptor to reduce renal inflammation and fibrosis, slowing renal function decline. Main IndicationsTreatment of adult patients with…
Opsumit® is the commercial brand name of Macitentan Tablets, an orally active dual endothelin receptor antagonist developed by Actelion. It blocks endothelin receptor subtypes ETₐ and ETᵦ on pulmonary vascular smooth muscle to dilate pulmonary arteries, lower pulmonary vascular resistance…
Adempas® is the commercial brand name of Riociguat Tablets, an orally active soluble guanylate cyclase stimulator developed by Bayer. It stimulates soluble guanylate cyclase to elevate intracellular cGMP concentration, dilate pulmonary vasculature and reduce pulmonary arterial pressure. Main IndicationsTreatment of…
Tracleer® is the commercial brand name of Bosentan Tablets, an orally active dual endothelin receptor antagonist developed by Actelion. It blocks endothelin ETₐ and ETᵦ receptors on pulmonary vascular smooth muscle to relax pulmonary arteries, reduce pulmonary vascular resistance and…